阿巴塞普和恶性瘤的风险:跨疾病指示的元分析
Benjamin P Zuckerman1, Mark Gibson1, Ritika Roy2
1Centre for Rheumatic Diseases, King's College London, SE5 9RJ, UK.
Rheumatology (Oxford, England)
|February 24, 2025
概括
在临床试验中,与安慰剂或TNF抑制剂相比,阿巴cept的使用没有增加癌症风险. 然而,观察性研究表明,阿巴塔塞普与其他生物药物相比,恶性瘤发病率更高.
科学领域:
- 类风湿病学 类风湿病学
- 在瘤学瘤学.
- 药物监督 药物监督 药物监督
背景情况:
- 阿巴切是一种用于治疗自身免疫性疾病的生物疗法,如类风湿性关节炎.
- 了解与阿巴塔塞普特相关的潜在癌症风险对于患者的安全至关重要.
研究的目的:
- 评估阿巴塔切普与患恶性瘤的风险之间的关联,不包括非黑色素瘤皮肤癌.
- 为了比较用阿巴切治疗的患者与安慰剂和其他疾病修饰性抗风湿药物 (DMARDs) 治疗的患者的癌症发病率.
主要方法:
- 系统的文献搜索确定了随机临床试验 (RCT),长期扩展研究 (LTE) 和观察队列,直到2024年4月.
- 进行了网络和对对的元分析,以比较恶性瘤发病率.
- 研究将阿塔切普与安慰剂,瘤亡因子抑制剂 (TNFi),常规合成DMARDs (csDMARDs) 以及其他生物/向合成DMARDs (b/tsDMARDs) 相比较.
主要成果:
- 在RCT/LTEs中,与安慰剂 (IRR0.58) 或TNFi (IRR0.72) 相比,阿巴切的使用与恶性瘤的不同发病率没有显著相关.
- 观察数据表明,与其他b/tsDMARD相比,阿巴塔塞普的恶性瘤发病率更高 (IRR 1.21).
- 在观察性研究中,在阿巴塔cept和csDMARDs之间没有观察到恶性瘤发病率的显著差异 (IRR 0.97).
结论:
- 在受控试验环境中,相比于安慰剂或TNFi,阿巴塔塞普与恶性瘤的风险增加无关.
- 观察数据表明,在与其他b/tsDMARDs相比,当阿巴塔塞普特与其他b/tsDMARDs相比,恶性瘤的潜在风险增加.
- 需要进一步的药监监测,以最终评估阿巴塔塞普特对癌症风险的影响.
更多相关视频
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.0K
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
423
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
